RNA-Targeting Small Molecule Drugs Icon

Cambridge Healthtech Institute’s 3rd Annual

RNA-Targeting Small Molecule Drugs

Novel Approaches to Modulate RNA Binding, Interactions and Function

April 20-21, 2022

 

There has been an increased understanding of diverse RNA moieties in the cell, their structure, function and interactions with proteins and other molecules. RNA has been targeted for therapeutic intervention using other RNA entities like small interfering RNA (siRNA), antisense and aptamers. Only recently have scientists started exploring small molecules to target RNA, as they offer more structural diversity, oral bioavailability, and better drug-like properties. However, defining which RNA to target, how to target it and its biological implications, are not quite understood. Understanding the characteristics of disease-related RNA and finding the appropriate small molecules to create good RNA-ligand interactions to elicit the necessary physiological response, is not trivial. Challenges also exist in terms of specificity, selectivity, and safety of these small molecules in vivo. The conference on RNA-Targeting Small Molecule Drugs will highlight some of the innovative approaches being pursued to find new small molecule drugs for modulating RNA for therapeutic intervention.

 

Coverage will likely include:

 

  • Tools for identifying the right RNA target for small molecule intervention
  • Characterizing the structural and physicochemical RNA-small molecule interactions for hit selection
  • Strategies for characterization and lead optimization of the RNA-targeting molecules
  • Biophysical/phenotypic screening for identifying and quantifying small molecule-RNA binding
  • Probing RNA-protein binding interactions
  • Optimizing the efficacy and safety of candidates for development 

 

If you would like to submit a proposal to give a presentation at this meeting, please click here.

 

The deadline for priority consideration is October 1, 2021.

 

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

We hope you can join us for this and the 3 concurrent day-and-a-half conferences during the second half of our 17th Annual Drug Discovery Chemistry event. Registering for this conference lets you also move back and forth among parallel programs to create your own agenda, whether you join in person or virtually.

 

For more details on the conference, please contact:

Tanuja Koppal, PhD

Senior Conference Director

Cambridge Healthtech Institute

Email: tkoppal@healthtech.com

 

For partnering and sponsorship information, please contact:

Aimee Croke
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5458
Email: acroke@cambridgeinnovationinstitute.com